The basolateral amygdala regulates adaptation to stress via β-adrenergic receptor-mediated reductions in phosphorylated extracellular signal-regulated kinase.
The reactivity of physiological systems and behavior to psychological stress is reduced with increasing familiarity with a repeated stressor. This reduced reactivity, termed habituation, is a crucial adaptation limiting negative health consequences of stress and can be disrupted in psychopathology. We hypothesized that the ability to habituate physiologically and behaviorally to previously experienced stressors depends on β-adrenergic receptor activation (β-AR) in the basolateral amygdala (BLA), a specific neural substrate important for the consolidation of multiple types of memories. We observed that administration of the β-AR antagonist propranolol into the BLA after each of four daily exposures to restraint stress prevented the normal development of neuroendocrine and behavioral habituation measured during the fifth restraint in adult male rats. In contrast, the β-AR agonist clenbuterol administered into the BLA after each restraint on days 1-4 enhanced neuroendocrine habituation at the lowest dose but attenuated behavioral habituation at high doses. We then explored intracellular signaling mechanisms in the BLA that might be a target of β-AR activation during stress. β-AR activation post restraint is necessary for the alteration in basal phosphorylated ERK (pERK) levels, as daily post-stress β-AR blockade on days 1-4 prevented repeated stress from leading to decreased pERK in the BLA on day 5. Finally, we examined the effect of blocking ERK phosphorylation in the BLA after each restraint on days 1-4 with the MEK (MAPK/ERK kinase) inhibitor U0126, and found that this was sufficient to both mimic neuroendocrine habituation in stress-naive animals and to enhance it in repeatedly stressed animals during restraint on day 5. Together, the results suggest that an individual's ability to habituate to repeated stress is regulated by activation of BLA β-AR, which may have these effects by transducing subsequent reductions in pERK. Individual variations in β-AR activation and intracellular signaling in the BLA may contribute significantly to adaptation to psychological stress and consequent resilience to stress-related psychopathology.
Department of Psychology, University of Michigan, Ann Arbor, MI 48104, USA.
N M
NM
Grissom
S
S
Bhatnagar
D000223:Adaptation, Psychological / Q000187:drug effects / Q000502:physiology*; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000679:Amygdala / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D000818:Animals; D002070:Butadienes / Q000494:pharmacology; D002976:Clenbuterol / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D008297:Male; D009570:Nitriles / Q000494:pharmacology; D010766:Phosphorylation / Q000187:drug effects; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011943:Receptors, Adrenergic, beta / Q000502:physiology*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*; D013315:Stress, Psychological / Q000378:metabolism* / Q000503:physiopathology*
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D002070:Butadienes; D009570:Nitriles; D011943:Receptors, Adrenergic, beta; C113580:U 0126; D011433:Propranolol; D048049:Extracellular Signal-Regulated MAP Kinases; D002976:Clenbuterol
Exp Neurol. 2007 Jul;206(1):126-36
17537436
Learn Mem. 2005 Sep-Oct;12(5):527-32
16204205
Endocrinology. 1997 Oct;138(10):4351-7
9322950
J Neurosci Methods. 1980 Dec;3(2):129-49
6110810
Amino Acids. 2010 Jan;38(1):75-84
19037712
Neuroscience. 2010 Sep 29;170(1):138-48
20600641
Mol Neurobiol. 2003 Feb;27(1):99-106
12668903
Eur J Neurosci. 2008 May;27(9):2250-61
18445216
Neuroscience. 2004;126(1):9-19
15145069
Am J Physiol Endocrinol Metab. 2005 Nov;289(5):E823-8
15956051
Brain Res. 2007 Dec;1186:212-23
18001698
Neurochem Res. 2005 Jan;30(1):61-7
15756933
Annu Rev Neurosci. 2004;27:1-28
15217324
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1328-33
12538851
J Neuroendocrinol. 2007 Mar;19(3):198-207
17280593
Neuropsychopharmacology. 2009 Dec;34(13):2733-45
19710634
Endocrinology. 2009 Feb;150(2):749-61
18845631
Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9371-6
15967994
Neurobiol Learn Mem. 1999 Jul;72(1):8-12
10371711
Endocrinology. 1973 May;92(5):1367-75
4348647
Eur J Pharmacol. 2008 May 13;585(2-3):492-501
18423443
Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13908-13
12361983
Behav Neurosci. 2004 Jun;118(3):563-8
15174933
Neuroscience. 1998 Jun;84(4):1025-39
9578393
Eur J Pharmacol. 2008 Apr 7;583(2-3):174-85
18282566
CNS Neurol Disord Drug Targets. 2006 Oct;5(5):485-501
17073652
Neuropsychopharmacology. 2010 Aug;35(9):1886-96
20410872
Neuron. 2007 Oct 4;56(1):19-32
17920012
Horm Behav. 2005 Apr;47(4):430-8
15777808
Behav Brain Res. 2008 Aug 22;191(2):219-26
18466984
Horm Behav. 2007 Jan;51(1):95-103
17054953
J Neuroendocrinol. 2010 Feb;22(2):92-101
20002965
Biol Psychiatry. 2002 Jan 15;51(2):189-92
11822998
J Neurosci Res. 2009 Jun;87(8):1823-31
19224582
Neuroscience. 2006;138(3):901-10
16310958
Behav Neurosci. 2008 Apr;122(2):282-92
18410168
J Physiol. 1998 Jul 15;510 ( Pt 2):605-14
9706007
Life Sci. 1985 Jun 3;36(22):2085-92
2987634
Neuroscience. 2006 Dec 1;143(2):387-93
16962717
Biol Psychiatry. 2003 Nov 1;54(9):947-9
14573324
Prog Brain Res. 2008;170:29-39
18655869
Behav Brain Res. 2008 Mar 5;187(2):246-53
17959260
Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6741-6
16611726
J Neurosci. 2000 Nov 1;20(21):8177-87
11050141
Depress Anxiety. 2008;25(3):260-71
17354267
Neuroendocrinology. 1997 May;65(5):360-8
9158068
Psychopharmacology (Berl). 2009 Jan;202(1-3):3-14
18704369
Prog Neuropsychopharmacol Biol Psychiatry. 2005 Dec;29(8):1201-13
16271821
Eur J Neurosci. 2002 Feb;15(3):553-60
11876783
Eur J Neurosci. 2009 Sep;30(5):800-7
19712089
Behav Neurosci. 2008 Dec;122(6):1284-94
19045948
Behav Neurosci. 2008 Feb;122(1):210-23
18298264
J Neurosci. 2008 Jun 25;28(26):6642-51
18579737
Psychol Med. 2010 Nov;40(11):1839-48
20102667
J Neuroendocrinol. 2002 May;14(5):403-10
12000546
Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10718-23
16020527
Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20529-34
21059919
J Neurosci. 2004 Feb 11;24(6):1385-92
14960610
Eur J Neurosci. 2005 Jan;21(1):283-9
15654867
Neuroscience. 2004;128(4):667-73
15464275
Behav Brain Res. 2006 Apr 25;169(1):176-80
16445993
Neuroscience. 2004;129(2):267-72
15501585
J Neurosci. 2002 Aug 1;22(15):6810-8
12151561
Biol Psychiatry. 2007 Apr 15;61(8):966-73
17137559
J Neurosci. 2007 Nov 7;27(45):12358-66
17989300
Neurobiol Learn Mem. 2002 Jan;77(1):119-24
11749089
J Psychiatr Res. 2008 May;42(6):503-6
17588604
Endocrinology. 2006 Oct;147(10):4917-30
16809449